Pediatric cryptosporidiosis: An evaluation of health care and societal costs in Peru, Bangladesh and Kenya.

Cryptosporidium is a leading cause of pediatric diarrhea in resource-limited settings; yet, few studies report the health care costs or societal impacts of this protozoan parasite. Our study examined direct and indirect costs associated with symptomatic cryptosporidiosis in infants younger than 12 m...

Full description

Bibliographic Details
Main Authors: Ellen R Rafferty, Janna M Schurer, Michael B Arndt, Robert K M Choy, Eugenio L de Hostos, David Shoultz, Marwa Farag
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5568228?pdf=render
_version_ 1819020878350909440
author Ellen R Rafferty
Janna M Schurer
Michael B Arndt
Robert K M Choy
Eugenio L de Hostos
David Shoultz
Marwa Farag
author_facet Ellen R Rafferty
Janna M Schurer
Michael B Arndt
Robert K M Choy
Eugenio L de Hostos
David Shoultz
Marwa Farag
author_sort Ellen R Rafferty
collection DOAJ
description Cryptosporidium is a leading cause of pediatric diarrhea in resource-limited settings; yet, few studies report the health care costs or societal impacts of this protozoan parasite. Our study examined direct and indirect costs associated with symptomatic cryptosporidiosis in infants younger than 12 months in Kenya, Peru and Bangladesh. Inputs to the economic burden model, such as disease incidence, population size, health care seeking behaviour, hospital costs, travel costs, were extracted from peer-reviewed literature, government documents, and internationally validated statistical tools for each country. Indirect losses (i.e. caregiver income loss, mortality, and growth faltering) were also estimated. Our findings suggest that direct treatment costs per symptomatic cryptosporidiosis episode were highest in Kenya ($59.01), followed by Peru ($23.32), and Bangladesh ($7.62). The total annual economic impacts for the 0-11 month cohorts were highest in Peru ($41.5M; range $0.88-$599.3M), followed by Kenya ($37.4M; range $1.6-$804.5M) and Bangladesh ($9.6M, range $0.28-$91.5M). For all scenarios, indirect societal costs far outweighed direct treatment costs. These results highlight the critical need for innovative improvements to current prevention, diagnostic and treatment strategies available in resource poor settings, as well as the need for solutions that span multiple disciplines including food and water safety, sanitation and livestock production.
first_indexed 2024-12-21T03:58:12Z
format Article
id doaj.art-7d0698d006754217ba0f980c14e25784
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-21T03:58:12Z
publishDate 2017-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-7d0698d006754217ba0f980c14e257842022-12-21T19:16:47ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01128e018282010.1371/journal.pone.0182820Pediatric cryptosporidiosis: An evaluation of health care and societal costs in Peru, Bangladesh and Kenya.Ellen R RaffertyJanna M SchurerMichael B ArndtRobert K M ChoyEugenio L de HostosDavid ShoultzMarwa FaragCryptosporidium is a leading cause of pediatric diarrhea in resource-limited settings; yet, few studies report the health care costs or societal impacts of this protozoan parasite. Our study examined direct and indirect costs associated with symptomatic cryptosporidiosis in infants younger than 12 months in Kenya, Peru and Bangladesh. Inputs to the economic burden model, such as disease incidence, population size, health care seeking behaviour, hospital costs, travel costs, were extracted from peer-reviewed literature, government documents, and internationally validated statistical tools for each country. Indirect losses (i.e. caregiver income loss, mortality, and growth faltering) were also estimated. Our findings suggest that direct treatment costs per symptomatic cryptosporidiosis episode were highest in Kenya ($59.01), followed by Peru ($23.32), and Bangladesh ($7.62). The total annual economic impacts for the 0-11 month cohorts were highest in Peru ($41.5M; range $0.88-$599.3M), followed by Kenya ($37.4M; range $1.6-$804.5M) and Bangladesh ($9.6M, range $0.28-$91.5M). For all scenarios, indirect societal costs far outweighed direct treatment costs. These results highlight the critical need for innovative improvements to current prevention, diagnostic and treatment strategies available in resource poor settings, as well as the need for solutions that span multiple disciplines including food and water safety, sanitation and livestock production.http://europepmc.org/articles/PMC5568228?pdf=render
spellingShingle Ellen R Rafferty
Janna M Schurer
Michael B Arndt
Robert K M Choy
Eugenio L de Hostos
David Shoultz
Marwa Farag
Pediatric cryptosporidiosis: An evaluation of health care and societal costs in Peru, Bangladesh and Kenya.
PLoS ONE
title Pediatric cryptosporidiosis: An evaluation of health care and societal costs in Peru, Bangladesh and Kenya.
title_full Pediatric cryptosporidiosis: An evaluation of health care and societal costs in Peru, Bangladesh and Kenya.
title_fullStr Pediatric cryptosporidiosis: An evaluation of health care and societal costs in Peru, Bangladesh and Kenya.
title_full_unstemmed Pediatric cryptosporidiosis: An evaluation of health care and societal costs in Peru, Bangladesh and Kenya.
title_short Pediatric cryptosporidiosis: An evaluation of health care and societal costs in Peru, Bangladesh and Kenya.
title_sort pediatric cryptosporidiosis an evaluation of health care and societal costs in peru bangladesh and kenya
url http://europepmc.org/articles/PMC5568228?pdf=render
work_keys_str_mv AT ellenrrafferty pediatriccryptosporidiosisanevaluationofhealthcareandsocietalcostsinperubangladeshandkenya
AT jannamschurer pediatriccryptosporidiosisanevaluationofhealthcareandsocietalcostsinperubangladeshandkenya
AT michaelbarndt pediatriccryptosporidiosisanevaluationofhealthcareandsocietalcostsinperubangladeshandkenya
AT robertkmchoy pediatriccryptosporidiosisanevaluationofhealthcareandsocietalcostsinperubangladeshandkenya
AT eugenioldehostos pediatriccryptosporidiosisanevaluationofhealthcareandsocietalcostsinperubangladeshandkenya
AT davidshoultz pediatriccryptosporidiosisanevaluationofhealthcareandsocietalcostsinperubangladeshandkenya
AT marwafarag pediatriccryptosporidiosisanevaluationofhealthcareandsocietalcostsinperubangladeshandkenya